368 related articles for article (PubMed ID: 30827921)
1. Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).
Goto A; Abe S; Koshiba S; Yamaguchi K; Sato N; Kurahashi Y
Drug Metab Pharmacokinet; 2019 Apr; 34(2):148-154. PubMed ID: 30827921
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
3. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F
Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536
[TBL] [Abstract][Full Text] [Related]
4. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
Colburn WA; Lee JW
Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic studies in drug product development.
Meibohm B; Derendorf H
J Pharm Sci; 2002 Jan; 91(1):18-31. PubMed ID: 11782894
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics/pharmacodynamics model-supported early drug development.
Chen B; Dong JQ; Pan WJ; Ruiz A
Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
[TBL] [Abstract][Full Text] [Related]
8. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research.
Tuntland T; Ethell B; Kosaka T; Blasco F; Zang RX; Jain M; Gould T; Hoffmaster K
Front Pharmacol; 2014; 5():174. PubMed ID: 25120485
[TBL] [Abstract][Full Text] [Related]
9. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
Bellissant E; Courcier-Duplantier S; Blin O;
Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
[TBL] [Abstract][Full Text] [Related]
10. PK/PD modelling and simulations: utility in drug development.
Rajman I
Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
[TBL] [Abstract][Full Text] [Related]
11. How do the top 12 pharmaceutical companies operate safety pharmacology?
Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
[TBL] [Abstract][Full Text] [Related]
12. Study design and statistical analysis of toxicokinetics: a report of JPMA investigation of case studies.
Igarashi T; Yabe T; Noda K
J Toxicol Sci; 1996 Dec; 21(5):497-504. PubMed ID: 9035061
[TBL] [Abstract][Full Text] [Related]
13. Development of translational pharmacokinetic-pharmacodynamic models.
Mager DE; Jusko WJ
Clin Pharmacol Ther; 2008 Jun; 83(6):909-12. PubMed ID: 18388873
[TBL] [Abstract][Full Text] [Related]
14. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
Gieschke R; Steimer JL
Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
[TBL] [Abstract][Full Text] [Related]
15. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
Singh AP; Shin YG; Shah DK
Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
[TBL] [Abstract][Full Text] [Related]
16. [Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia].
Iida K; Yano T; Ikemori M; Ishida T; Nishimura N
Yakugaku Zasshi; 2021 Jun; 141(6):877-886. PubMed ID: 33642438
[TBL] [Abstract][Full Text] [Related]
17. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.
Ploeger BA; van der Graaf PH; Danhof M
Drug Metab Pharmacokinet; 2009; 24(1):3-15. PubMed ID: 19252332
[TBL] [Abstract][Full Text] [Related]
18. Using exposure-response and biomarkers to streamline early drug development.
Venitz J
Ernst Schering Res Found Workshop; 2007; (59):47-63. PubMed ID: 17117714
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on non-clinical safety evaluation of drug metabolites through the JSOT workshop.
Minagawa T; Nakano K; Furuta S; Iwasa T; Takekawa K; Minato K; Koga T; Sato T; Kawashima K; Kurahashi Y; Onodera H; Naito S; Nakamura K
J Toxicol Sci; 2012; 37(4):667-73. PubMed ID: 22863847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
